Idiopathic pulmonary arterial hypertension (IPAH) is pathogenetically related to low levels of
the vasodilator nitric oxide (NO). Because NO regulates cellular respiration and …

Hypoxic pulmonary hypertension complicates many primary respiratory and cardiac
conditions. To define the potential role of endothelial nitric oxide (NO) further in both the …

We have previously demonstrated that arterial, but not venous, vasodilatory responses to
endothelium-derived nitric oxide (EDNO)-dependent agonists are enhanced in lungs …

Pulmonary endothelial cells normally synthesize prostacyclin (PGI2) and nitric oxide (NO),
which are both potent vasodilators. Although PGI2 is largely used to treat patients with …

Pulmonary arterial hypertension (PAH) is a fatal disease characterized by impaired
regulation of pulmonary hemodynamics and excessive growth and dysfunction of the …

Alterations in nitric oxide signaling have been hypothesized to have an etiologic role in the
development of hypoxic pulmonary hypertension. However, changes in the expression of …

Background Pulmonary hypertension is characterized by abnormal thickening of the
pulmonary arteries and increased pulmonary vascular resistance. Nitric oxide is a potent …

Decreased production of vasodilator substances such as nitric oxide (NO) has been
proposed as important in development of pulmonary arterial hypertension (PAH). We …

Endothelial nitric oxide (NO) synthase (eNOS) mRNA and protein and NO production are
increased in hypoxia-induced hypertensive rat lungs, but it is uncertain whether eNOS gene …

Chronic hypoxia induces pulmonary hypertension and right ventricular (RV) hypertrophy.
Nitric oxide (NO) has been proposed to modulate the pulmonary vascular response to …